Compoundeer Logo
COMPOUNDEER
Uncovering Potential
RankingCompaniesDCF
INBX Logo

Inhibrx, Inc.

INBX

Biological Products, (No Diagnostic Substances)

Mkt Cap

$940.3M

PE

-4.98

Debt

$205.7M

Cash

$337.3M

EV

$808.7M

FCF

-$168.5M

Market Cap

$940.3M

P/E Ratio

-4.98

Debt

$205.7M

Cash

$337.3M

EV

$808.7M

FCF

-$168.5M

Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.

Sector

  • ACLX Logo

    ACLX

  • ADMA Logo

    ADMA

  • ADPT Logo

    ADPT

  • ALEC Logo

    ALEC

  • ALLO Logo

    ALLO

  • AMGN Logo

    AMGN

  • AURA Logo

    AURA

  • AVXL Logo

    AVXL

  • BCRX Logo

    BCRX

  • BEAM Logo

    BEAM

  • BIIB Logo

    BIIB

  • BLUE Logo

    BLUE

  • CABA Logo

    CABA

  • CGEM Logo

    CGEM

  • CRBU Logo

    CRBU

  • CRSP Logo

    CRSP

  • DNLI Logo

    DNLI

  • EDIT Logo

    EDIT

  • EXEL Logo

    EXEL

  • FDMT Logo

    FDMT

  • GILD Logo

    GILD

  • HALO Logo

    HALO

  • HLVX Logo

    HLVX

  • ICVX Logo

    ICVX

  • IMVT Logo

    IMVT

  • IOVA Logo

    IOVA

  • ITOS Logo

    ITOS

  • KRYS Logo

    KRYS

  • KYMR Logo

    KYMR

  • MRNA Logo

    MRNA

  • NBIX Logo

    NBIX

  • NVAX Logo

    NVAX

  • PCVX Logo

    PCVX

  • PRME Logo

    PRME

In the chart Earnings are multiplied by this value.

Earnings Growth -
Earnings Stability -


Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12-201912-202012-202112-2022TTM
Net Margin-390%-590%-1.1K%-6.6K%-43K%
ROA-170%-47%-51%-44%-45%
ROE55%-100%-160%-250%-150%

What is the average Net Margin?

The average Net Margin over the past 5 years is -3.88K%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is -5.49K%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is -47.64%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is +6.5%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is -203.12%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is -94.05%.


Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12-201912-202012-202112-2022TTM
Debt FCF--0.59-0.87-1.74-1.22
Debt Equity-0.360.391.353.481.59
MIN
Graham Stability-----

What is the Debt/FCF?

The Debt/FCF trailing twelve month is -1.22.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -0.87.

What is the Graham’s Stability?

Graham’s Stability measure stands at -.


Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12-201912-2021Trend
Revenue-45%-70%-34%
Net Income---
Stockholders Equity-11%41%
FCF---

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is -.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is -33.62%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is -.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is -.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is +41.43%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is -.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -.